We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Patch Painlessly Tests for Glucose in Diabetics

By LabMedica International staff writers
Posted on 05 May 2009
A skin patch could one day provide a less-invasive alternative for diabetics who need to take regular samples of their own blood to keep glucose levels in check.

The patch, approximately the size of a deck of cards, contains four micro-needles that "bite" sequentially at programmed intervals. More...
The needles are electronically controlled to penetrate the skin deep enough to draw blood from a capillary, but not deep enough to hit a nerve. This means patients would experience little or no pain. The patch could be worn anywhere on the body where it could obtain accurate readings of capillary blood.

Electrical engineers from the Schulich School of Engineering at the University of Calgary (Alberta, Canada) have patented the device, which they dubbed the Electronic Mosquito. A sensor in each cell of the e-Mosquito measures sugar levels in the blood. These data can then be sent wirelessly to a remote device such as a computer or a monitoring instrument worn on the wrist. The system could even be connected to an alarm to alert patients or doctors when blood sugar levels enter the danger zone. The currently used method of drawing blood from fingertips and using glucose-testing strips can be painful, inconvenient, and time-consuming.

"This is a dramatic improvement over manual poking, particularly for children and elderly patients," said Martin Mintchev, director of the Low Frequency Instrumentation Lab at the Schulich School of Engineering. "Our approach is radically different and offers a reliable, repeatable solution with the minor inconvenience of wearing something similar to an adhesive bandage."

Eventually, the biomedical engineers intend to integrate a pump system so insulin injections can also become autonomous based on data from the e-Mosquito, thus converting the device into an external artificial pancreas.

Approximately 246 million people around the world are affected by diabetes. More than two million Canadians have diabetes, a number that is increasing because of the aging population and rising obesity rates, according to the Canadian Diabetes Association.

Related Links:
Schulich School of Engineering at the University of Calgary



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.